Revolution Medicines, Inc. (RVMD)
NASDAQ: RVMD · Real-Time Price · USD
76.32
+2.66 (3.61%)
Nov 25, 2025, 4:00 PM EST - Market closed
Revolution Medicines Stock Forecast
Stock Price Forecast
The 18 analysts that cover Revolution Medicines stock have a consensus rating of "Strong Buy" and an average price target of $77.11, which forecasts a 1.04% increase in the stock price over the next year. The lowest target is $64 and the highest is $99.
Price Target: $77.11 (+1.04%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Revolution Medicines stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 8 | 7 | 9 | 10 | 9 |
| Buy | 5 | 5 | 6 | 7 | 6 | 9 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 13 | 13 | 16 | 16 | 18 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wolfe Research | Wolfe Research | Buy Initiates $75 | Buy | Initiates | $75 | -1.73% | Nov 18, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $71 → $82 | Buy | Maintains | $71 → $82 | +7.44% | Nov 6, 2025 |
| Wedbush | Wedbush | Buy Maintains $77 → $80 | Buy | Maintains | $77 → $80 | +4.82% | Nov 6, 2025 |
| Needham | Needham | Strong Buy Maintains $66 → $72 | Strong Buy | Maintains | $66 → $72 | -5.66% | Nov 6, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $72 → $73 | Strong Buy | Maintains | $72 → $73 | -4.35% | Nov 6, 2025 |
Financial Forecast
Revenue This Year
3.98M
Revenue Next Year
25.37M
from 3.98M
Increased by 537.73%
EPS This Year
-5.47
from -3.58
EPS Next Year
-6.16
from -5.47
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 43.8M | 183.4M | |||
| Avg | 4.0M | 25.4M | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 4,511.4% | |||
| Avg | - | 537.7% | |||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -5.02 | -4.69 | |||
| Avg | -5.47 | -6.16 | |||
| Low | -5.51 | -7.54 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.